Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart Kupfer

Showing results (11-20 of 99) with videos related to

Pageof 10
Sort By:
Journal of Clinical Hypertension (Greenwich, Conn.)|March 6, 2018
Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney diseaseGeorge L Bakris, Lin Zhao, Stuart Kupfer, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|October 23, 2009
Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockersGeorge L Bakris, Rhonda M Cooper-Dehoff, Qian Zhou, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 18, 2025
Toward a Quantitative Understanding of Aficamten Clinical Pharmacology: Population Pharmacokinetic ModelingDonghong Xu, Hanbin Li, Stephen B Heitner, et al.
Stroke|February 10, 2007
Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)Robert Wilcox, Marie-Germaine Bousser, D John Betteridge, et al.
Hypertension (Dallas, Tex. : 1979)|February 2, 2011
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertensionWilliam B White, Michael A Weber, Domenic Sica, et al.
Blood Pressure Monitoring|January 22, 2014
Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertensionMichael A Weber, William B White, Domenic Sica, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|January 29, 2011
The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressureGeorge L Bakris, Domenic Sica, Michael Weber, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|July 19, 2011
Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoringDomenic Sica, William B White, Michael A Weber, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|October 11, 2018
Efficacy and safety of azilsartan medoxomil/chlortalidone fixed-dose combination in hypertensive patients uncontrolled on azilsartan medoxomil alone: A randomized trialDavid J Collier, Attila Juhasz, Enrico Agabiti-Rosei, et al.
Journal of Hypertension|January 16, 2018
A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertensionWilliam C Cushman, George L Bakris, William B White, et al.
Pageof 10

Showing results (11-20 of 99) with videos related to

Sort By:
Pageof 10
Journal of Clinical Hypertension (Greenwich, Conn.)|March 6, 2018
Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney diseaseGeorge L Bakris, Lin Zhao, Stuart Kupfer, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|October 23, 2009
Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockersGeorge L Bakris, Rhonda M Cooper-Dehoff, Qian Zhou, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 18, 2025
Toward a Quantitative Understanding of Aficamten Clinical Pharmacology: Population Pharmacokinetic ModelingDonghong Xu, Hanbin Li, Stephen B Heitner, et al.
Stroke|February 10, 2007
Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)Robert Wilcox, Marie-Germaine Bousser, D John Betteridge, et al.
Hypertension (Dallas, Tex. : 1979)|February 2, 2011
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertensionWilliam B White, Michael A Weber, Domenic Sica, et al.
Blood Pressure Monitoring|January 22, 2014
Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertensionMichael A Weber, William B White, Domenic Sica, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|January 29, 2011
The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressureGeorge L Bakris, Domenic Sica, Michael Weber, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|July 19, 2011
Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoringDomenic Sica, William B White, Michael A Weber, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|October 11, 2018
Efficacy and safety of azilsartan medoxomil/chlortalidone fixed-dose combination in hypertensive patients uncontrolled on azilsartan medoxomil alone: A randomized trialDavid J Collier, Attila Juhasz, Enrico Agabiti-Rosei, et al.
Journal of Hypertension|January 16, 2018
A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertensionWilliam C Cushman, George L Bakris, William B White, et al.
Pageof 10